Home / Market News / $LEGN
benzinga Corporate Catalyst Impact 55/100 ● negative

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

Oct 13, 2026, 4:20 PM UTC · Primary ticker $LEGN

Barclays analyst Etzer Darout reiterated an Overweight rating on Legend Biotech but reduced the price target from $74 to $68. This indicates a continued positive outlook on the company's long-term prospects despite a slightly tempered near-term valuation.

Barclays analyst Etzer Darout maintained an 'Overweight' rating on Legend Biotech, signaling a continued positive long-term view on the company. However, the price target was lowered from $74 to $68, suggesting a slight adjustment in the analyst's valuation model or near-term expectations. This move is moderately impactful for traders, as it reaffirms a positive stance while acknowledging potential headwinds or a more conservative outlook on future growth. For LEGN, the short-term implication could be a neutral to slightly negative reaction due to the price target reduction, but the maintained 'Overweight' rating offers long-term reassurance. The key opportunity for traders lies in understanding if this price target adjustment reflects broader industry trends or company-specific developments that might not be immediately apparent.

$LEGN neutral Analyst maintains Overweight rating but lowers price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.